GGrantIndex
← Search

Gene Analysis

$493,515P30FY2009CANIH

Mayo Clinic Rochester, Rochester MN

Investigators

Linked publications, trials & patents

Trial NCT06508463Trial NCT06387979Trial NCT06381154Trial NCT06353191Trial NCT06315595Trial NCT06271291Trial NCT06238648Trial NCT06207188Trial NCT06160206Trial NCT06115772Trial NCT06078709Trial NCT06075524Trial NCT06073951Trial NCT06058663Trial NCT05917145Trial NCT05910801Trial NCT05720624Trial NCT05717153Trial NCT05704283Trial NCT05703399Trial NCT05674123Trial NCT05653661Trial NCT05640765Trial NCT05612100Trial NCT05591092Trial NCT05584449Trial NCT05575440Trial NCT05560009Trial NCT05557877Trial NCT05556525Trial NCT05549661Trial NCT05547386Trial NCT05547347Trial NCT05541016Trial NCT05530759Trial NCT05526417Trial NCT05523154Trial NCT05518903Trial NCT05512767Trial NCT05507879Trial NCT05507541Trial NCT05497804Trial NCT05465954Trial NCT05465941Trial NCT05447923Trial NCT05447910Trial NCT05443971Trial NCT05438563Trial NCT05417867Trial NCT05416983Trial NCT05412953Trial NCT05411523Trial NCT05411497Trial NCT05410977Trial NCT05407038Trial NCT05407025Trial NCT05403580Trial NCT05399004Trial NCT05393713Trial NCT05392946Trial NCT05388877Trial NCT05388851Trial NCT05388058Trial NCT05388006Trial NCT05356897Trial NCT05294367Trial NCT05288062Trial NCT05269381Trial NCT05246670Trial NCT05232851Trial NCT05224271Trial NCT05222620Trial NCT05212428Trial NCT05199285Trial NCT05194293Trial NCT05176223Trial NCT05168163Trial NCT05130060Trial NCT05112627Trial NCT05112614Trial NCT05111314Trial NCT05077735Trial NCT05075980Trial NCT05053100Trial NCT05045066Trial NCT05033288Trial NCT05030298Trial NCT05018208Trial NCT05005182Trial NCT04999826Trial NCT04975516Trial NCT04967196Trial NCT04926948Trial NCT04925817Trial NCT04917744Trial NCT04906369Trial NCT04897009Trial NCT04895735Trial NCT04892277Trial NCT04892264

Abstract

The Gene Analysis Shared Resource (GASR) provides Mayo Clinic Cancer Center researchers efficient, high-quality, cost-effective access to state-of-the-art genomics technologies for studying gene structure and function. Since 2003, the GASR components have been working in a coordinated fashion to provide technical expertise, instrumentation, and coordinated support for DMA sequencing, gene expression profiling, and genotyping. Support for gene expression regulation through RNAi analysis was added in 2007. The services provided by the facility include large-scale, full-service re-sequencing analysis using ABI 3730x1 sequencers, plus comprehensive genotyping and gene transcript analysis using Affymetrix Genechip[unreadable] technology and Illumina BeadChips. Recent additions to our capabilities include Agilent array CGH and miRNA analysis as well as NextGen sequencing on an Illumina 1G Genome Analyzer Since the last competitive grant renewal, more than 130 Cancer Center members have used the services offered by the GASR and Cancer Center projects account for about two-thirds of all the activity in the GASR. The primary goals of the GASR are to bring cutting edge genomic technologies to Mayo researchers and to do so at an affordable price. This includes, but is not limited to: i. maintaining solid expertise in the use of well-defined commercial platforms for genomic analysis and translating this knowledge into high quality data for Cancer Center members, ii. continued exploration, validation, and implementation of new technologies which will advance the capabilities of the GASR to provide cutting edge genomic assays, iii. enhancement of the utility of archived and fresh clinical samples by developing methodologies which allow for the use of very small amounts of ribonucleic acid from formalin fixed, paraffin embedded (FFPE) and laser-captured microdissected tissues, iv. exploration of new technologies, such as "next generation sequencing," and miRNA profiling based on input from users of the GASR for continuous improvement. In addition, we will continue to work closely with bioinformatics and biostatistics to insure seamless interpretation of the data generated through GASR services.

View original record on NIH RePORTER →